At Olema Oncology we leverage our deep understanding of endocrine-driven cancers, nuclear receptors and mechanisms of acquired resistance with the goal of transforming the standard of care for pre- and post-menopausal women living with cancer by developing more convenient and effective therapies. Our current focus is OP-1250, a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD) that is currently being studied in a Phase 1/2 clinical trial for the treatment of metastatic or locally advanced ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. We have aspirations to develop OP-1250 in a number of other ER+ breast cancer indications, both as a monotherapy and in combination with approved therapies that have shown synergistic effects with other endocrine therapies.
Join us as we aim to design therapies for improving lives.
